From ๐ฑ๐ฐ| Living in ๐ฆ๐บ| She/Her | Redmond Barry Distinguished Professor and Head of Allergy and Lung Health Unit @ALHU_MSPGH @UniMelbMDHS @unimelbMSPGH
Honoured to be elected as a @AAHMS_health fellow last night. Thank you to all my mentors, collaborators and @ALHU_MSPGH for their important contributions to my career. @UniMelbMDHS @unimelbMSPGH
A leader in the life course of chronic lung diseases, she has changed global understanding of how lung disease #COPD originates, leading to new practices, policy and a new field of research, pre-COPD.
Welcome Distinguished Prof @Cdharmage as a new #AAHMSFellow. @UniMelbMDHS
@donsin4 Well done Rosa. Nice to see that the interest in pre-COPD is exponentially increasing. Let's keep the momentum going until we find interventions to arrest its progression to COPD.
Recipient of the 2025 NHMRC Elizabeth Blackburn Investigator Grant Award for leadership in public health, @CDharmage has dedicated her research career to redefining COPD as a preventable life course condition, shifting the focus from late diagnosis to early intervention. Read more on Professor Dharmageโs career in her own words on our website: https://t.co/k61pM6evc6
A study 10 years in the making, just published in @LancetRespirMed
How do DPP1 inhibitors really work in bronchiectasis?
We show a novel mechanism for treatment efficacy, by inhibiting Azurocidin-1, a ciliotoxin, DPP1i can enhance mucociliary clearance.
https://t.co/eVR7fhgW7w
I am honoured and deeply humbled by Elizabeth Blackburn Award for Leadership in Public Health. Thank you @NHMRC for supporting my career and research for nearly 2.5 decades.
Congratulations to each of the 2025 Research Excellence Awardees honoured tonight for their success and thank you for sharing NHMRCโs vision of building a Healthy Australia. Read the full list of award winners on our website: https://t.co/hv2CkG9qxl
Our latest paper just out in @LancetRespirMed
10 unanswered questions about DPP1 inhibition in bronchiectasis
We outline key future clinical and research questions after the approval of the first new therapy for people with bronchiectasis.
Congratulations Jiahui, Chloe and @MereteLong
Chronic Obstructive Pulmonary Disease (COPD) is common and treatable but often diagnosed too late. NHMRC funded researcher Professor Shyamali Dharmage (@MDHS_UniMelb) is leading a world first trial of triple therapy to halt lung damage in pre-COPD #WorldCOPDDay
Stay tuned for Cure-Adire. Time that we put our resources together. Funded by MRFF, this project will commence in early 2026. As the lead, I like to thank all the PIs of respiratory studies for coming together for this grant application.
Excited to learn about CURE-AIDRE which is a database of 75,000 asthma samples, decades in the making. It will be the engine to drive the search for treatments and cure. @CDharmage@tomiosifidis
๐Now on Peeref: Paternal prepubertal passive smoke exposure is related to impaired lung function trajectories from childhood to middle age in their offspring
๐: https://t.co/K8Z4ZICcX6
๐๏ธ: Altmetric: 285
@CDharmage@mishra_gita@ThoraxBMJ
๐ฌ"Exposure to passive (second-hand) smoke๐ฌ not only harms the children at that time but may also affect the lung health of their future children,โ Dinh S. Bui, PhD, and @CDharmage, MBBS, MSc, MD, PhD, @unimelbMSPGH, told Healio.
https://t.co/GuxObLGUo0
Lets promote and advance the field of pre-COPD. Recognising and tackling the pre-disease and early disease states have helped reducing the burden of many chronic diseases, so why not in COPD? https://t.co/Jn1DrYTpV5
Grateful to @LancetRespirMed for the kind profile. Honoured and humbled to be featured. Thank you.
Shyamali Dharmage: mapping lung health trajectories across the life course - The Lancet Respiratory Medicine https://t.co/v9tQDJYk7o